PROTEA BIOPHARMA

PROTEA biopharma N.V. is a Belgian biopharma company developing improved diagnostics and therapeutics for infectious and chronic immune diseases that affect millions of people worldwide... PROTEA biopharma's activities started in 1998, with the acquisition of a license from Temple University, USA. This license granted to the Company the exclusive rights to commercialize a new marker for chronic fatigue syndrome (CFS-ME), based on the detection of an abnormal form of Ribonuclease L, an enzyme involved in antiviral defense. In 1999 the Company raised 3.3 million euro in equity investment and recruited a multidisciplinary team of scientists with experience in cell and molecular biology, biochemistry and immunology... Over the past ten years the Company has developed an extensive and unique expertise in the field of innate immunity and antiviral pathways. Besides CFS-ME, our research activities have extended to other chronic immune conditions (MS, inflammatory and auto-immune diseases),..

Also known as: PROTEA biopharma N.V.

Primary location: Diegem Belgium